Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Centre Hospitalier Universitaire de Caen · Université Claude Bernard Lyon 1 · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
971
total citations
- FWCI
- 57.50
- Percentile
- 100%
- References
- 39
Citations per year
Authors
21- GZGérard ZalcmanCorresponding
Centre Hospitalier Universitaire de Caen, Université Claude Bernard Lyon 1, Assistance Publique – Hôpitaux de Paris, Université Paris Cité
- JMJulien Mazières
Hôpital Larrey
- JMJ. Margery
Institut Gustave Roussy
- LGLaurent Greillier
Assistance Publique Hôpitaux de Marseille
- CAClarisse Audigier-Valette
Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer
Topics & keywords
Topics
Keywords
- Medicine
- Pemetrexed
- Mesothelioma
- Bevacizumab
- Internal medicine
- Malignant pleural effusion
- Oncology
- Pleurodesis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.